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Abstract
Multiple Sclerosis is an inflammatory, auto-immune, neurodegenerative disease of the central 
nervous system. The disease has a prevalence of approx 1:700 with at least 2.5 million cases 
worldwide. It is the leading, non-trauma cause of physical disability among young and mid-
dle-aged adults. Recently developed therapies do reduce disease activity but only modestly, 
with all of the available agents producing significant side effects that reduce compliance, and/
or serious risk for adverse events. Relaxin has been long-recognized to play a critical role in 
pregnancy. Recent investigations have revealed that relaxin may be an important regulator of 
inflammation and immune processes. This is due to the ability of relaxin to promote the pro-
duction of glucocorticoid receptors, increase serum levels of the adrenocorticotropic hormone 
and inhibiting cell-mediated pro-inflammatory activity by stimulation of the peroxisome prolif-
erator-activated receptor gamma. This study found serum relaxin levels to be elevated in sub-
jects with multiple sclerosis. Production of relaxin is down regulated by a negative feedback 
loop through its own receptor binding. Decreased receptor binding may contribute to the high-
er level of relaxin seen in these patients and may lead to dysregulation of the inflammatory and 
immune pathways.
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Introduction
Multiple sclerosis (MS) is an inflammatory, auto-immune disease of the central 
nervous system (CNS). It has a world-wide in distribution, with more than 2.5 mil-
lion cases. It is the cause of eventual severe disability in 75-85% of subjects devel-
oping the disease (Weinshenker, 1998; Kantarci and Weinshenker, 2005). The recogni-
tion that MS is a largely an inflammatory, auto-reactive lymphocyte-driven disease 
has led to the development of therapeutic strategies that have resulted in a decrease 
in the risk of clinical relapses, reduction in the progression of lesion burden on mag-
netic resonance imaging scans, and in some cases reduced disability progression 
over the short term, generally for 2 to 3 years (Bornstein et al., 1987; Jacobs et al., 
1996; PRISMS Study Group, 1999; Durell et al., 2002). It is not known whether there 
is significant therapy-induced long term reduction in risk of disability progression, 
although there are some recent data supporting the proposal that relapse reduction, 
particularly early in the disease course, may be associated with less disability pro-
gression (Bermel et al., 2010).
It is well-known that multiple sclerosis clinical disease activity abates during 
pregnancy (Lorenzi and Ford, 2002). Although the mechanism(s) of these chang-
es are not fully understood they are thought to be due to the rise in estrogen levels 
during pregnancy (Gold and Voskuhl, 2009). Early clinical trials using the estrogen 
β-estradiol in MS have shown encouraging results (Sicotte et al., 2002) and several 
phase II studies are currently underway (Gold and Voskuhl, 2009). 
One possible mechanism of action for β-estradiol is through its ability to up-regu-
late the expression of relaxin 2 (RLX2), a peptide member of the insulin superfamily 
(Lao Guico and Sherwood, 1985). Other members include RLX1and RLX3. RLX1 and 
RLX2 have been shown to bind the same receptors, but are differentially expressed 
(Hansell, 1991). Both RLX1 and RLX2 are up-regulated by glucocorticoids, but only 
RLX2 is up-regulated by sex hormones, suggesting different biological roles for RLX1 
and RLX2 (Garibay-Tupas et al., 2004). In contrast, RLX3 is expressed primarily in 
the brain where is acts as a neurotransmitter and is involved in feeding and stress 
responses (Bathgate et al., 2013). 
RLX2 is detected transiently in the plasma of both men and women (Moriatis Wolf 
et al., 2013) and has been studied extensively in pregnancy, cardiovascular disease 
and renal disease (Bathgate et al., 2013). From these studies we know that RLX2 is a 
pleiotropic protein which exhibit enhanced binding in the presence of β-estradiol (Wil-
son et al., 2005; Santora et al., 2007; Figueiredo et al., 2009). The receptors for RLX2 
(and RLX1) are RLX family peptide receptors (RXFP-1 and RXFP-2), the glucocorticoid 
receptor (GCR) and estrogen receptor beta (ERB) (Dschietzig, et al. 2004; Sherwood, 
2004). These regulate pathways which are currently being researched in MS. 
Binding to RXFP-1 increases PPARγ transcription activity via RXFP-1 (Hsu SY et 
al., 2002, Bathgate et al., 2006) without increasing PPARγ mRNA or PPARγ protein 
levels (Singh and Bennett, 2010). This is a pathway of great interest in MS because 
other PPAR agonist, such as pioglitazone and rosiglitazone also have antiglycemic 
and anti-inflammatory properties (Bright et al., 2008), inhibit mitogen-stimulated 
T-cell proliferation as well as tumor necrosis factor alpha (TNFα) and interferon gam-
ma (IFNγ) production (Schmidt et al., 2004). In experimental allergic encephalomyeli-
tis (EAE), an animal model of MS, pioglitazone reduce lymphocyte proliferation and 
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infiltration into the CNS (Niino et al., 2001), blocks interleukin (IL)-12 induced dif-
ferentiation of pro-inflammatory CD4+ helper T cells into type 1 helper cells (Shevach 
et al., 1999), reduces gene expression for IL-1β and IL-6, reduces production of TNFα 
and IFNγ and reduces clinical disease expression (Feinstein et al., 2002; Natarajan 
and Bright, 2002; Klotz et al., 2005). In addition, PPARγ gene knockout mice are more 
susceptible to developing EAE (Natarajan et al., 2003) and in limited studies in MS 
patients PPARγ expression appeared reduced in peripheral immune cells and these 
cells have reduced responsiveness to PPARγ agonists (Pershadsingh et al., 2004). 
Binding to GCR elicits a potent anti-inflammatory and immuno-regulating 
response (Newton, 2000). These have been well studied in MS and GCR agonists are 
the primary approach to treating acute attacks of the disease (Citterio et al., 2000).
In vitro studies of ERB agonists have shown that they have neuroprotective effects 
(Wisdom et al., 2013) and the ability to promote remyelination (Crawford et al., 2010). 
Agonists of the ERB have been primarily studied in MS through the actions of sex 
hormones. These studies have shown that binding of estrogen to ERB is one mecha-
nism through which estrogen treatment was neuroprotective and promoted recovery 
from exacerbations (Gold and Voskuhl, 2009). 
The interest in a possible role for RLX in MS was further supported by chromo-
somal localization of both RLX1 and RLX2 at 9p24.1 (Garibay-Tupas et al., 1999), an 
area identified in linkage studies as a susceptibility locus for MS (Patsopoulos and 
de Bakker, 2011). The location of the RLX genes at 9p24.1 together with their diverse 
actions supported the investigation of RLX in subjects with MS. 
Materials and methods
Sample Collection
Serum and plasma samples were obtained from controls (n=14, 8 females and 4 
males, aged 36-62 years) and MS patients (n=16, 10 females and 6 males, aged 34-64 
years) by venipuncture, randomized and assayed blind. The study and consent forms 
were approved by the internal review board.
Relaxin Levels
Relaxin levels (pg/ml) were measured in serum by ELISA (Immundiagnostik AG, 
Germany) according to the manufacturer’s instructions. 
DNA Sequencing
Isolation of genomic DNA samples was carried out using the QIAamp DNA 
Blood Mini Kits (Qiagen) according to the manufacturers protocol. Briefly, 200 µl of 
buffy coat was added to a solution of Proteinase , RNase A and lysis buffer. The mix-
ture was incubated at 56°C for 10 minutes. Next, 200 µl of 100% ethanol were add-
ed to the sample and mixed pulse-vortexing for 15 seconds. The solution was then 
applied to a QIAamp spin column (Qiagen) placed in a 2 ml collection tube and cen-
trifuged at 6000 x g for 1 minute. The spin column was then placed in a clean 2 ml 
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collection tube and re-centrifuged at full speed for 15 seconds. Wash buffer 1 (500 µl) 
was added to the column and centrifuged at 6000 x g for 1 minute. The spin column 
was placed in a clean 2 ml collection tube and 500 µl of wash buffer 2 was added. 
The column was then centrifuged at full speed for 3 minutes. The spin column was 
then placed in a new 2 ml collection tube and centrifuged at full speed for 1 minute. 
Finally, the spin column was placed in a clean 1.5 ml microcentrifuge tube and 200 µl 
of distilled water were added to the column. After incubating at room temperature 
for 5 minutes, the DNA was eluted by centrifugation at 6000 x g for 1 minute. The 
eluate was collected and stored at -800C prior to sequencing. The target genes (RLX1 
& RLX2) were then sequenced using published primer pairs (Fu and Evans,1992). 
Protein Modeling
The binding affinity of RLX has been shown to be dependent on conformational 
and electrostatic forces (Bathgate et al., 2013). To determine if changes in the DNA 
sequence of RLX could affect the receptor binding region, protein modeling was 
done. These models were based on the known structure of human RLX using Swis-
sprot (Arnold,  2006; Bordoli, 2009).
Results 
Serum RLX levels
Relaxin was not detected in the control group. However, there were two distinct 
cohorts in the MS group. RLX was detected in cohort 1 (56% of subjects) but not 
detected in cohort 2 (44% of subjects, see Tab. 1). The elevated RLX levels did not 
correlate with differences in age, sex or duration of disease. But there was a moder-
ate correlation between RLX levels and weeks since last exacerbation. Correlation co-
efficient was calculated by the Pearson method (r = ∑((X - My)(Y - Mx)) / √((SSx)(SSy) 
R = -0.6825, P-Value = 0.043008. (see Fig. 1).
DNA Sequencing
No mutations were detected in the sequence for RLX2. However, there were a 
number of sequence changes in the gene for RLX1:





Sex Age (years)Mean (range)
Serum relaxin
(pg/ml)
MS Cohort 1 13.1 (7-19) 5 F, 4 M 45 (39-56) 124.54 (15.79-279.88)
MS Cohort 2 12.0 (1-32) 5 F, 2 M 39 (34-64) 0
Control 8 F, 4 M 50 (36-62) 0
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RLX1-WT = L E F C L L L N Q F S R A V A A K W K D D V I K L C G R E L V 
RLX1-MS = L G V C L L L N Q F S R A V A D S W M E E V I K L C G R E L V 
Protein modeling
Protein modeling suggests that the changes in the amino acid sequence could 
affect RLX1 conformation and electrostatic forces (see Fig. 2). 
!!!!!! !
Figure 1 – Subjects in cohort 1 had measurable levels of relaxin in the sera and there was a moderate corre-
lation with the amount of time since last exacerbation. Correlation co-efficient was calculated by the Pearson 
method; R = -0.6825, P-Value = 0.043008.
Figure 2 – Conformational and electrostatic changes in the B chain binding cassette of relaxin 1 from sub-
jects with MS compared to controls. Blue indicates positive charge, red indicates negative charge. Changes 
in the electrostatic forces of relaxin 1 could potentially affect the ability of relaxin to bind to its receptors.
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Discussion
Relaxin levels and activity were measured in sera from non-pregnant subjects with 
MS and controls. These results showed that serum RLX levels were detectable in 56% 
of subjects with MS and not detected in any of the control samples. The highest serum 
RLX levels were detected in those who had experienced recent inflammatory events, 
although this was a weak correlation. Some of the subjects expressing RLX had levels 
of RLX in the sera usually only observed in pregnancy (>250 pg/ml). The circulating 
RLX that we detected could be either RLX1 or RLX2, or a combination of both. The 
reason for its presence is unclear but could possibly be due to a number of factors.
Chronic cerebral inflammation is a hallmark of MS and is transiently present in 
both relapsing remitting and progressive forms of the disease (Weiner, 2009). Inflam-
mation increases the expression of glucocorticoids (Black, 2002) which in turn can 
up-regulate the expression of RLX1 and RLX2 (Garibay-Tupas, 2004). The underly-
ing presence of chronic inflammation in subjects with MS could explain the detection 
of relatively high levels of circulating RLX in these subjects. Another possible source 
of RLX in the circulation might be from RLX expression in the brain. The RLXs pro-
duced in the CNS might migrate through the blood brain barrier which is disrupted 
in MS (Minagar and Alexander, 2003).
Another possible factor contributing to elevated levels of circulating RLX is the 
disruption of auto-regulation through binding to GCR. Auto-regulation has been 
described in this way for RLX2 (Dschietzig et al., 2009). Since RLX1 and RLX2 are 
both regulated through the GCR they may share this common auto-regulation. The 
mutations described in the gene encoding RLX1 in MS might disrupt GCR binding 
and any auto-regulation of RLX1 production through this mechanism. 
The presence of circulating RLX outside of pregnancy suggests a role for RLX in 
other than reproductive biology. Perumal and Dhanasekaran (2014) recently suggest-
ed a role for RLX in systemic lupus erythematosus. Lupus is an inflammatory, auto-
immune disease which has been genetically linked to MS (Mandel et al., 2004). To 
clarify the role of RLX, if any, in MS further research needs to be undertaken to iden-
tify the circulating RLX and its source. It is possible that sera RLX is a biomarker of 
inflammation, due to leakage across the blood brain barrier or its presence might be 
due to disrupted auto-regulation. In any case, it presents a new pathway of research 
in MS. And further studies of a possible role of RLX in MS may provide targets for 
the development of novel therapeutics.
Conflict of Interest
The authors have no conflict of interest to declare.
References
Arnold K., Bordoli L., Kopp J., Schwede T. (2006). The SWISS-MODEL Workspace: A 
web-based environment for protein structure homology modelling. Bioinformatics 
22: 195-201.
57Relaxin in multiple sclerosis
Bathgate R.A., Ivell R., Sanborn B.M., Sherwood O.D., Summers R.J. (2006) Interna-
tional union of pharmacology LVII: recommendations for the nomenclature of 
receptors for relaxin family peptides. Pharmacol. Rev. 58: 7-31. 
Bathgate R.A., Halls M.L., van der Westhuizen E.T., Callander G.E., Kocan M., Summers 
R.J. (2013) Relaxin family peptides and their receptors. Physiol. Rev. 93: 405-480.
Bermel R.A., Weinstock-Guttman B., Bourdette D., Foulds P., You X., Rudick R.A. 
(2010) Intramuscular interferon beta-1a therapy in patients with relapsing-remit-
ting multiple sclerosis: a 15-year follow-up study. Mult. Scler. 16: 588-596. 
Black P.H. (2002) Stress and the inflammatory response: A review of neurogenic 
inflammation. Brain Behav. Immun. 16: 622-653.
Bordoli L., Kiefer F., Arnold K., Benkert P., Battey J., Schwede T. (2009). Protein struc-
ture homology modelling using SWISS-MODEL Workspace. Nature Protocols 4: 1.
Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., 
Merriam A., Wassertheil-Smoller S., Spada V. (1987) A pilot trial of Cop 1 in exac-
erbating-remitting multiple sclerosis. N. Engl. J. Med. 317: 408-414.
Bright J.J., Kanakasabai S., Chearwae W., Chakraborty S. (2008) PPAR regulation of 
inflammatory signaling in CNS diseases. PPAR Res. 2008: 658520. 
Citterio A., La Mantia L., Ciucci G., Candelise L., Brusaferri F., Midgard R., Filippini 
G. (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. 
Cochrane Database of Systematic Reviews 4: CD001331.
Crawford D.K., Mangiardi M., Song B., Patel R., Du S., Sofroniew M.V., Voskuhl R.R., 
Tiwari-Woodruff S.K. (2010) Oestrogen receptor β ligand: a novel treatment to 
enhance endogenous functional remyelination. Brain 133: 2999–3016. 
Dschietzig T., Bartsch C., Stangl V., Baumann G., Stangl K. (2004) Identification of the 
pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J. 18: 1536-
1538. 
Dschietzig T., Bartsch C., Wessler S., Baumann G., Stangl K. (2009) Autoregulation 
of human relaxin-2 gene expression critically involves relaxin and glucocorticoid 
receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter. 
Regul. Pept. 155: 163-173.
Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., Montanari E., Zaf-
faroni M. (2002) Independent comparison of interferon (INCOMIN) trial study 
group. Every-other-day interferon beta-1b versus once-weekly interferon beta-
1a for multiple sclerosis: results of a 2-year prospective randomised multicentre 
study (INCOMIN). Lancet 359: 1453-1460. 
Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-
Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., Heneka M.T. (2002) 
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental 
autoimmune encephalomyelitis. Ann. Neurol. 51: 694-702. 
Figueiredo K.A., Rossi G., Cox M.E. (2009) Relaxin promotes clustering, migration, 
and activation states of mononuclear myelocytic cells. Ann. N. Y. Acad. Sci. 1160: 
353-360.
Fu P and Evans B. (1992) A novel PCR method for amplifying exons (or genes) 
over intragenic (or intergenic) regions in the genome. Nucl. Acids Res. 20:2903 
doi:10.1093/nar/20.11.2903.
Garibay-Tupas J.L., Csiszar K., Fox M., Povey S., Bryant-Greenwood G.D. (1999) 
Analysis of the 5’-upstream regions of the human relaxin H1 and H2 genes and 
58 Roy Garvin, Alasdair Burns
their chromosomal localization on chromosome 9p24.1 by radiation hybrid and 
breakpoint mapping. J. Mol. Endocrinol. 23: 355-365.
Garibay-Tupas J.L., Okazaki K.J., Tashima L.S., Yamamoto S., Bryant-Greenwood G.D. 
(2004) Regulation of the human relaxin genes H1 and H2 by steroid hormones. 
Mol. Cell. Endocrinol. 219: 115-125.
Gold S.M., Voskuhl R.R. (2009) Estrogen and testosterone therapies in multiple sclero-
sis. Prog. Brain Res. 175: 239–251.
Hansell D.J., Bryant-Greenwood G.D., Greenwood F.C. (1991) Expression of the 
human relaxin H1 gene in the decidua, trophoblast, and prostate. J. Clin. Endo-
crinol. Metab. 72: 899-904.
Hsu S.Y., Nakabayashi K., Nishi S., Kumagai J., Kudo M., Sherwood O.D., Hsueh A.J. 
(2002) Activation of orphan receptors by the hormone relaxin. Science 295: 671-
674.
Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., 
Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., 
Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dough-
erty D.S., Kinkel R.P., Mass M.K., Munschauer F.E. 3rd, Priore R.L., Pullicino P.M., 
Scherokman B.J., Whitham R.H. (1996) Intramuscular interferon beta-1a for dis-
ease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collabora-
tive Research Group (MSCRG). Ann. Neurol. 39: 285-294. 
Kantarci O.H., Weinshenker B.G. (2005) Natural history of multiple sclerosis. Neurol. 
Clin. 23: 17-38. 
Klotz L., Schmidt M., Giese T., Sastre M., Knolle P., Klockgether T., Heneka M.T. (2005) 
Proinflammatory stimulation and pioglitazone treatment regulate peroxisome pro-
liferator-activated receptor gamma levels in peripheral blood mononuclear cells 
from healthy controls and multiple sclerosis patients. J. Immunol. 175: 4948-4955. 
Lao Guico M.S., Sherwood O.D. (1985) Effect of oestradiol-17β on ovarian and serum 
concentrations of relaxin during the second half of pregnancy in the rat. J. Reprod. 
Fert. 74: 65-70.
Lorenzi A.R., Ford H.L. (2002) Multiple sclerosis and pregnancy. Postgrad. Med. J. 78: 
460–464.
Mandel M., Gurevich M., Pauzner R., Kaminski N., Achiron A. (2004) Autoimmunity 
gene expression portrait: specific signature that intersects or differentiates between 
multiple sclerosis and systemic lupus erythematosus. Clin. Exp. Immunol. 138: 
164-170.
Minagar A., Alexander S. (2003) Blood-brain barrier disruption in multiple sclerosis. 
Mult. Scler. 9: 540-549.
Moriatis Wolf J., Cameron K.L., Clifton K.B., Owens B.D. (2013) Serum relaxin levels 
in young athletic men are comparable with those in women. Orthopedics 36: 128-
131.
Natarajan C., Bright J.J. (2002) Peroxisome proliferator-activated receptor-gamma ago-
nists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, 
IL-12 signaling and Th1 differentiation. Genes Immun. 3: 59-70.
Natarajan C., Muthian G., Barak Y., Evans R.M., Bright J.J. (2003) Peroxisome prolif-
erator-activated receptor-gamma-deficient heterozygous mice develop an exacer-
bated neural antigen-induced Th1 response and experimental allergic encephalo-
myelitis. J. Immunol. 171: 5743-5750. 
59Relaxin in multiple sclerosis
Newton R. (2000) Molecular mechanisms of glucocorticoid action: what is important? 
Thorax 55: 603-613.
Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., 
Onoé K. (2001) Amelioration of experimental autoimmune encephalomyelitis in 
C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. 
J. Neuroimmunol. 116: 40-48.
Patsopoulos N., de Bakker P. (2011) Genome-wide meta-analysis identifies novel mul-
tiple sclerosis susceptibility loci. Ann. Neurol. 70: 897–912.
Pershadsingh H.A., Heneka M.T., Saini R., Amin N.M., Broeske D.J., Feinstein D.L. 
(2004) Effect of pioglitazone treatment in a patient with secondary multiple sclero-
sis. J. Neuroinflammation 1: 3.
Perumal M.B., Dhanasekaran S. (2014) Relaxin: a missing link in the pathomecha-
nisms of systemic lupus erythematosus? Mod. Rheumatol. 24: 547-551.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously 
in Multiple Sclerosis) Study Group. (1998) Randomised double-blind placebo-con-
trolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 
352: 1498-1504. 
Santora K., Rasa C., Visco D., Steinetz B.G., Bagnell C.A. (2007) Antiarthritic effects of 
relaxin, in combination with estrogen, in rat adjuvant-induced arthritis. J. Pharma-
col. Exp. Ther. 322: 887-893.
Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D.L., Heneka M.T. (2004) Anti-
inflammatory and antiproliferative actions of PPAR-gamma agonists on T-lym-
phocytes derived from MS patients. J. Leukoc. Biol. 75: 478-485. 
Sherwood O.D. (2004) Relaxin’s physiological roles and other diverse actions. Endocr. 
Rev. 25: 205-234. 
Shevach E.M., Chang J.T., Segal B.M. (1999) The critical role of IL-12 and the IL-12R 
beta 2 subunit in the generation of pathogenic autoreactive Th1 cells. Springer 
Semin. Immunopathol. 21: 249-262.
Sicotte N.L., Liva S.M., Klutch R., Pfeiffer P., Bouvier S., Odesa S. (2002) Treatment of 
multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52: 421–428.
Singh S., Bennett R.G. (2010) Relaxin signaling activates peroxisome proliferator-acti-
vated receptor gamma. Mol. Cell. Endocrinol. 315: 239-245. 
Weiner H.L. (2009) The challenge of multiple sclerosis: how do we cure a chronic het-
erogeneous disease? Ann. Neurol. 65: 239-248.
Weinshenker B.G. (1998) The natural history of multiple sclerosis: update 1998. Sem-
in. Neurol. 18: 301-307.
Wilson B.C., Milne P., Saleh T.M. (2005) Relaxin pretreatment decreases infarct size in 
male rats after middle cerebral artery occlusion. Ann. N. Y. Acad. Sci. 1041: 223-
228. 
Wisdom A.J., Cao Y., Itoh N., Spence R.D., Voskuhl R.R. (2013) Estrogen receptor-β 
ligand treatment after disease onset is neuroprotective in the multiple sclerosis 
model. J. Neurosci. Res. 91: 901-908.
